NCT07276399
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07276399
Title A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-5)
Acronym OrigAMI-5
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | BRA | AUS


No variant requirements are available.